Binding mode prediction of conformationally restricted anandamide analogs within the CB1 receptor
Tóm tắt
CB1 cannabinoid receptors are G-protein coupled receptors for endocannabinoids including anandamide and 2-arachidonoylglycerol. Because these arachidonic acid metabolites possess a 20-carbon polyene chain as the alkyl terminal moiety, they are highly flexible with the potential to adopt multiple biologically relevant conformations, particularly those in a bent form. To better understand the molecular interactions associated with binding and steric trigger mechanisms of receptor activation, a series of conformationally-restricted anandamide analogs having a wide range of affinity and efficacy were evaluated. A CB1 receptor model was constructed to include the extracellular loops, particularly extracellular loop 2 which possesses an internal disulfide linkage. Using both Glide (Schrödinger) and Affinity (Accelrys) docking programs, binding conformations of six anandamide analogs were identified that conform to rules applicable to the potent, efficacious and stereoselective non-classical cannabinoid CP55244. Calculated binding energies of the optimum structures from both procedures correlated well with the reported binding affinity values. The most potent and efficacious of the ligands adopted conformations characterized by interactions with both the helix-3 lysine and hydrophobic residues that interact with CP55244. The other five compounds formed fewer or less energetically favorable interactions with these critical residues. The flexibility of the tested anandamide analogs, measured by torsion angles around the benzene as well as the stretch between side chain moieties, could contribute to the differences in ability to interact with the CB1 receptor. Analyses of multiple poses of conformationally-restricted anandamide analogs permitted identification of favored amino acid interactions within the CB1 receptor binding pocket. A ligand possessing both high affinity and cannabinoid agonist efficacy was able to interact with both polar and hydrophobic interaction sites utilized by the potent and efficacious non-classical cannabinoid CP55940. In contrast, other analogs characterized by reduced affinity or efficacy exhibited less favorable interactions with those key residues.
Tài liệu tham khảo
Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946–1949.
Mechoulam R, Ben Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, .: Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995, 50:83–90.
Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K: 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995, 215:89–97.
Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I, Mechoulam R: 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 2001, 98:3662–3665.
Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter P, Bymaster FP, Leese AB, Felder CC: Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002, 301:1020–1024.
Barnett-Norris J, Guarnieri F, Hurst DP, Reggio PH: Exploration of biologically relevant conformations of anandamide, 2-arachidonylglycerol, and their analogues using conformational memories. J Med Chem 1998, 41:4861–4872.
Bonechi C, Brizzi A, Brizzi V, Francioli M, Donati A, Rossi C: Conformational analysis of N-arachidonylethanolamide (anandamide) using nuclear magnetic resonance and theoretical calculations. Magnetic Resonance in Chemistry 2001, 39:432–437.
Chen JZ, Han XW, Xie XQ: Preferred conformations of endogenous cannabinoid ligand anandamide. Life Sci 2005, 76:2053–2069.
Lynch DL, Reggio PH: Molecular dynamics simulations of the endocannabinoid N-arachidonoylethanolamine (anandamide) in a phospholipid bilayer: probing structure and dynamics. J Med Chem 2005, 48:4824–4833.
Borngraber S, Browner M, Gillmor S, Gerth C, Anton M, Fletterick R, Kuhn H: Shape and specificity in mammalian 15-lipoxygenase active site. The functional interplay of sequence determinants for the reaction specificity. J Biol Chem 1999, 274:37345–37350.
Gan QF, Browner MF, Sloane DL, Sigal E: Defining the arachidonic acid binding site of human 15-lipoxygenase. Molecular modeling and mutagenesis. J Biol Chem 1996, 271:25412–25418.
Rowlinson SW, Kiefer JR, Prusakiewicz JJ, Pawlitz JL, Kozak KR, Kalgutkar AS, Stallings WC, Kurumbail RG, Marnett LJ: A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. J Biol Chem 2003, 278:45763–45769.
Berglund BA, Fleming PR, Rice KC, Shim JY, Welsh WJ, Howlett AC: Development of a novel class of monocyclic and bicyclic alkyl amides that exhibit CB1 and CB2 cannabinoid receptor affinity and receptor activation. Drug Des Discov 2000, 16:281–294.
Tong W, Collantes ER, Welsh WJ, Berglund BA, Howlett AC: Derivation of a pharmacophore model for anandamide using constrained conformational searching and comparative molecular field analysis. J Med Chem 1998, 41:4207–4215.
Shim JY, Howlett AC: Steric trigger as a mechanism for CB1 cannabinoid receptor activation. J Chem Inf Comput Sci 2004, 44:1466–1476.
Shim JY, Welsh WJ, Howlett AC: Homology model of the CB1 cannabinoid receptor: sites critical for nonclassical cannabinoid agonist interaction. Biopolymers 2003, 71:169–189.
Ghosh A, Rapp CS, Friesner RA: Generalized Born model based on a surface integral formulation. J Phys Chem B 1998, 102:10983–10990.
Mechoulam R, Hanus L, Martin BR: Search for endogenous ligands of the cannabinoid receptor. Biochem Pharmacol 1994, 48:1537–1544.
Busch-Petersen J, Hill WA, Fan P, Khanolkar A, Xie XQ, Tius MA, Makriyannis A: Unsaturated side chain beta-11-hydroxyhexahydrocannabinol analogs. J Med Chem 1996, 39:3790–3796.
Fay JF, Dunham TD, Farrens DL: Cysteine residues in the human cannabinoid receptor: only C257 and C264 are required for a functional receptor, and steric bulk at C386 impairs antagonist SR141716A binding. Biochemistry 2005, 44:8757–8769.
Lu R, Hubbard JR, Martin BR, Kalimi MY: Roles of sulfhydryl and disulfide groups in the binding of CP-55,940 to rat brain cannabinoid receptor. Mol Cell Biochem 1993, 121:119–126.
Gouldson P, Calandra B, Legoux P, Kerneis A, Rinaldi-Carmona M, Barth F, Le Fur G, Ferrara P, Shire D: Mutational analysis and molecular modelling of the antagonist SR 144528 binding site on the human cannabinoid CB(2) receptor. Eur J Pharmacol 2000, 401:17–25.
Shire D, Calandra B, Delpech M, Dumont X, Kaghad M, Le Fur G, Caput D, Ferrara P: Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A. J Biol Chem 1996, 271:6941–6946.
Karnik SS, Sakmar TP, Chen HB, Khorana HG: Cysteine residues 110 and 187 are essential for the formation of correct structure in bovine rhodopsin. Proc Natl Acad Sci U S A 1988, 85:8459–8463.
Doi T, Molday RS, Khorana HG: Role of the intradiscal domain in rhodopsin assembly and function. Proc Natl Acad Sci U S A 1990, 87:4991–4995.
Hwa J, Klein-Seetharaman J, Khorana HG: Structure and function in rhodopsin: Mass spectrometric identification of the abnormal intradiscal disulfide bond in misfolded retinitis pigmentosa mutants. Proc Natl Acad Sci U S A 2001, 98:4872–4876.
Davidson FF, Loewen PC, Khorana HG: Structure and function in rhodopsin: replacement by alanine of cysteine residues 110 and 187, components of a conserved disulfide bond in rhodopsin, affects the light-activated metarhodopsin II state. Proc Natl Acad Sci U S A 1994, 91:4029–4033.
Karnik SS, Gogonea C, Patil S, Saad Y, Takezako T: Activation of G-protein-coupled receptors: a common molecular mechanism. Trends Endocrinol Metab 2003, 14:431–437.
Murphy JW, Kendall DA: Integrity of extracellular loop 1 of the human cannabinoid receptor 1 is critical for high-affinity binding of the ligand CP 55,940 but not SR 141716A. Biochem Pharmacol 2003, 65:1623–1631.
Abood ME, Ditto KE, Noel MA, Showalter VM, Tao Q: Isolation and expression of a mouse CB1 cannabinoid receptor gene. Comparison of binding properties with those of native CB1 receptors in mouse brain and N18TG2 neuroblastoma cells. Biochem Pharmacol 1997, 53:207–214.
Ho BY, Zhao J: Determination of the cannabinoid receptors in mouse x rat hybridoma NG108–15 cells and rat GH4C1 cells. Neurosci Lett 1996, 212:123–126.
Okada T, Fujiyoshi Y, Silow M, Navarro J, Landau EM, Shichida Y: Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography. Proc Natl Acad Sci U S A 2002, 99:5982–5987.
Ulmschneider MB, Tieleman DP, Sansom MS: The role of extra-membranous inter-helical loops in helix-helix interactions. Protein Eng Des Sel 2005, 18:563–570.
Huffman JW, Mabon R, Wu MJ, Lu J, Hart R, Hurst DP, Reggio PH, Wiley JL, Martin BR: 3-Indolyl-1-naphthylmethanes: new cannabimimetic indoles provide evidence for aromatic stacking interactions with the CB(1) cannabinoid receptor. Bioorg Med Chem 2003, 11:539–549.
Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS: Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004, 47:1739–1749.
Kenakin T: Drug efficacy at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 2002, 42:349–379.
Melvin LS, Milne GM, Johnson MR, Subramaniam B, Wilken GH, Howlett AC: Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs. Mol Pharmacol 1993, 44:1008–1015.
Vinayagam A, Pugalenthi G, Rajesh R, Sowdhamini R: DSDBASE: a consortium of native and modelled disulphide bonds in proteins. Nucleic Acids Res 2004, 32:D200-D202.
Chen R, Li L, Weng Z: ZDOCK: an initial-stage protein-docking algorithm. Proteins 2003, 52:80–87.
Chen R, Weng Z: A novel shape complementarity scoring function for protein-protein docking. Proteins 2003, 51:397–408.
Luthy R, Bowie JU, Eisenberg D: Assessment of protein models with three-dimensional profiles. Nature 1992, 356:83–85.
Song ZH, Bonner TI: A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212–2. Mol Pharmacol 1996, 49:891–896.
Chin CN, Lucas-Lenard J, Abadji V, Kendall DA: Ligand binding and modulation of cyclic AMP levels depend on the chemical nature of residue 192 of the human cannabinoid receptor 1. J Neurochem 1998, 70:366–373.
Aqvist J, Marelius J: The linear interaction energy method for predicting ligand binding free energies. Comb Chem High Throughput Screen 2001, 4:613–626.